Bevacizumab - Genentech/Roche

Drug Profile

Bevacizumab - Genentech/Roche

Alternative Names: Avastin; RG-435; rhuMAb-VEGF; RO-4876646

Latest Information Update: 14 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech; Hackensack University Medical Center
  • Developer All Ireland Cooperative Oncology Research Group; Austrian Breast & Colorectal Cancer Study Group; Bayer; Beth Israel Deaconess Medical Center; Breast Cancer Research Foundation; Brigham and Women's Hospital; Bristol-Myers Squibb; Cancer and Leukemia Group B; Cancer Research UK; Chugai Pharmaceutical; Cincinnati Children's Hospital Medical Center; Dana-Farber Cancer Institute; Duke University; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; Genentech; Hackensack University Medical Center; Hoosier Cancer Research Network; Indiana University School of Medicine; Japan Breast Cancer Research Group; M. D. Anderson Cancer Center; Massachusetts General Hospital; Medical University of South Carolina; Melanoma Research Foundation Breakthrough Consortium; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National Comprehensive Cancer Network; NCIC Clinical Trials Group; North Central Cancer Treatment Group; NSABP Foundation; Ohio State University Medical Center; Peter MacCallum Cancer Centre; Roche; Royal Marsden NHS Foundation Trust; Sanofi; Sarcoma Alliance for Research through Collaboration; SCRI Development Innovations; South Eastern European Research Oncology Group; Spanish Cooperative Group for Digestive Tumour Therapy; Spanish Lung Cancer Group; Stanford University School of Medicine; SWOG; The Catalan Institute of Oncology; UNICANCER; University College London; University of Alabama at Birmingham; University of Arkansas System; University of California, Davis; University of Iowa; University of Oklahoma; University of Tennessee; University of Texas M. D. Anderson Cancer Center; US Oncology Research; West German Study Group; Xijing Hospital
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cervical cancer; Ovarian cancer; Glioblastoma; Pancreatic cancer; Renal cell carcinoma; Mesothelioma; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Cervical cancer; Colorectal cancer; Glioblastoma; Glioma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma
  • Registered Fallopian tube cancer; Peritoneal cancer
  • Phase III Head and neck cancer
  • Phase II Biliary cancer; Brain metastases; Endometrial cancer; Gynaecological cancer; Hodgkin's disease; Intestinal cancer; Liver cancer; Liver metastases; Malignant melanoma; Meningioma; Multiple myeloma; Neuroblastoma; Neurofibromatoses; Rectal cancer; Soft tissue sarcoma; Solid tumours; Urogenital cancer
  • Phase I/II Neoplastic meningitis; Sarcoma
  • Suspended Carcinoid tumour
  • Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Eye-Disorders; Gastric cancer; Gastrointestinal stromal tumours; Mesothelioma; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer

Most Recent Events

  • 29 Aug 2018 Roche initiates a phase I/II trial for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (NCT03555149)
  • 17 Aug 2018 Phase-III clinical trials in Fallopian tube cancer (First-line therapy, Combination therapy) in China (IV) (NCT03635489)
  • 17 Aug 2018 Phase-III clinical trials in Ovarian cancer (First-line therapy, Combination therapy) in China (IV) (NCT03635489)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top